This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
by Zacks Equity Research
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
by Zacks Equity Research
Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.
Best Momentum Stocks to Buy for March 15th
by Zacks Equity Research
CERT, BWMX and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 15, 2023.
New Strong Buy Stocks for March 15th
by Zacks Equity Research
TRIN, CERT, WPP, NUE and BHR have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2023.
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CERT vs. PBYI: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CERT vs. PBYI: Which Stock Is the Better Value Option?
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 1.53% and 76.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Matches Q1 Earnings Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -681.82% and 42.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.